269 related articles for article (PubMed ID: 25107591)
1. Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism.
Kivell B; Uzelac Z; Sundaramurthy S; Rajamanickam J; Ewald A; Chefer V; Jaligam V; Bolan E; Simonson B; Annamalai B; Mannangatti P; Prisinzano TE; Gomes I; Devi LA; Jayanthi LD; Sitte HH; Ramamoorthy S; Shippenberg TS
Neuropharmacology; 2014 Nov; 86():228-40. PubMed ID: 25107591
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A.
Simonson B; Morani AS; Ewald AW; Walker L; Kumar N; Simpson D; Miller JH; Prisinzano TE; Kivell BM
Br J Pharmacol; 2015 Jan; 172(2):515-31. PubMed ID: 24641310
[TBL] [Abstract][Full Text] [Related]
3. Modulation of serotonin transporter function by kappa-opioid receptor ligands.
Sundaramurthy S; Annamalai B; Samuvel DJ; Shippenberg TS; Jayanthi LD; Ramamoorthy S
Neuropharmacology; 2017 Feb; 113(Pt A):281-292. PubMed ID: 27743931
[TBL] [Abstract][Full Text] [Related]
4. D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism.
Bolan EA; Kivell B; Jaligam V; Oz M; Jayanthi LD; Han Y; Sen N; Urizar E; Gomes I; Devi LA; Ramamoorthy S; Javitch JA; Zapata A; Shippenberg TS
Mol Pharmacol; 2007 May; 71(5):1222-32. PubMed ID: 17267664
[TBL] [Abstract][Full Text] [Related]
5. The Kappa Opioid Receptor Agonist 16-Bromo Salvinorin A Has Anti-Cocaine Effects without Significant Effects on Locomotion, Food Reward, Learning and Memory, or Anxiety and Depressive-like Behaviors.
van de Wetering R; Ewald A; Welsh S; Kornberger L; Williamson SE; McElroy BD; Butelman ER; Prisinzano TE; Kivell BM
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375403
[TBL] [Abstract][Full Text] [Related]
6. Salvinorin A exerts opposite presynaptic controls on neurotransmitter exocytosis from mouse brain nerve terminals.
Grilli M; Neri E; Zappettini S; Massa F; Bisio A; Romussi G; Marchi M; Pittaluga A
Neuropharmacology; 2009; 57(5-6):523-30. PubMed ID: 19628000
[TBL] [Abstract][Full Text] [Related]
7. Stress produces aversion and potentiates cocaine reward by releasing endogenous dynorphins in the ventral striatum to locally stimulate serotonin reuptake.
Schindler AG; Messinger DI; Smith JS; Shankar H; Gustin RM; Schattauer SS; Lemos JC; Chavkin NW; Hagan CE; Neumaier JF; Chavkin C
J Neurosci; 2012 Dec; 32(49):17582-96. PubMed ID: 23223282
[TBL] [Abstract][Full Text] [Related]
8. O6C-20-nor-salvinorin A is a stable and potent KOR agonist.
Hirasawa S; Cho M; Brust TF; Roach JJ; Bohn LM; Shenvi RA
Bioorg Med Chem Lett; 2018 Sep; 28(16):2770-2772. PubMed ID: 29426768
[TBL] [Abstract][Full Text] [Related]
9. Kappa Opioid Receptor-Induced Aversion Requires p38 MAPK Activation in VTA Dopamine Neurons.
Ehrich JM; Messinger DI; Knakal CR; Kuhar JR; Schattauer SS; Bruchas MR; Zweifel LS; Kieffer BL; Phillips PE; Chavkin C
J Neurosci; 2015 Sep; 35(37):12917-31. PubMed ID: 26377476
[TBL] [Abstract][Full Text] [Related]
10. Kappa Opioid Receptor Mediated Differential Regulation of Serotonin and Dopamine Transporters in Mood and Substance Use Disorder.
Ragu Varman D; Jayanthi LD; Ramamoorthy S
Handb Exp Pharmacol; 2022; 271():97-112. PubMed ID: 34136961
[TBL] [Abstract][Full Text] [Related]
11. Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.
Schattauer SS; Kuhar JR; Song A; Chavkin C
Cell Signal; 2017 Apr; 32():59-65. PubMed ID: 28088389
[TBL] [Abstract][Full Text] [Related]
12. Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine.
Thompson AC; Zapata A; Justice JB; Vaughan RA; Sharpe LG; Shippenberg TS
J Neurosci; 2000 Dec; 20(24):9333-40. PubMed ID: 11125013
[TBL] [Abstract][Full Text] [Related]
13. Role of RGS12 in the differential regulation of kappa opioid receptor-dependent signaling and behavior.
Gross JD; Kaski SW; Schmidt KT; Cogan ES; Boyt KM; Wix K; Schroer AB; McElligott ZA; Siderovski DP; Setola V
Neuropsychopharmacology; 2019 Sep; 44(10):1728-1741. PubMed ID: 31141817
[TBL] [Abstract][Full Text] [Related]
14. Repeated exposure to the κ-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity.
Potter DN; Damez-Werno D; Carlezon WA; Cohen BM; Chartoff EH
Biol Psychiatry; 2011 Oct; 70(8):744-753. PubMed ID: 21757186
[TBL] [Abstract][Full Text] [Related]
15. Solving an Old Puzzle: Elucidation and Evaluation of the Binding Mode of Salvinorin A at the Kappa Opioid Receptor.
Puls K; Wolber G
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677775
[TBL] [Abstract][Full Text] [Related]
16. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment.
Verrico CD; Miller GM; Madras BK
Psychopharmacology (Berl); 2007 Jan; 189(4):489-503. PubMed ID: 16220332
[TBL] [Abstract][Full Text] [Related]
17. Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats.
Conti MM; Meadows SM; Melikhov-Sosin M; Lindenbach D; Hallmark J; Werner DF; Bishop C
Neuropharmacology; 2016 Nov; 110(Pt A):125-134. PubMed ID: 27452719
[TBL] [Abstract][Full Text] [Related]
18. Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum.
Gehrke BJ; Chefer VI; Shippenberg TS
Psychopharmacology (Berl); 2008 Apr; 197(3):509-17. PubMed ID: 18246329
[TBL] [Abstract][Full Text] [Related]
19. The profile of mephedrone on human monoamine transporters differs from 3,4-methylenedioxymethamphetamine primarily by lower potency at the vesicular monoamine transporter.
Pifl C; Reither H; Hornykiewicz O
Eur J Pharmacol; 2015 May; 755():119-26. PubMed ID: 25771452
[TBL] [Abstract][Full Text] [Related]
20. Rescue of dopamine transporter function in hypoinsulinemic rats by a D2 receptor-ERK-dependent mechanism.
Owens WA; Williams JM; Saunders C; Avison MJ; Galli A; Daws LC
J Neurosci; 2012 Feb; 32(8):2637-47. PubMed ID: 22357848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
